L-Leucine: A Comprehensive Reference
1. Identity and Chemical Characterization
Systematic and common names: Leucine, or leucin (symbol Leu or L), is an essential amino acid used in the biosynthesis of proteins. The biologically active form is L-leucine (CAS No. 61-90-5), which is chemically designated as (S)-2-amino-4-methylpentanoic acid. There are three stereoisomers associated with leucine: L-leucine (the biologically active form found in proteins), D-leucine (which does not occur naturally within proteins), and racemic mixtures containing both forms.
Structural classification: Leucine is an α-amino acid, meaning it contains an α-amino group (which is in the protonated −NH₃⁺ form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO⁻ form under biological conditions), and a side chain isobutyl group, making it a non-polar aliphatic amino acid. L-leucine, together with L-isoleucine and L-valine, is called one of the three branched-chain amino acids (BCAAs).
Molecular properties: The chemical formula for leucine is C₆H₁₃NO₂, with a molecular weight of approximately 131.17 g/mol. This white crystalline powder has notable physical properties; it melts at temperatures exceeding 300°C and has limited solubility in water — about 22.4 grams per liter at room temperature. It is a white shiny hexahedral crystal or white crystalline powder at room temperature, odorless, and slightly bitter.
Etymology: Leucine is named after the Greek word for 'white': λευκός (leukós, 'white'), after its common appearance as a white powder, a property it shares with many other amino acids.
Genetic encoding: L-leucine is encoded by the codons UUA, UUG, CUU, CUC, CUA, and CUG.
Metabolic classification: The primary metabolic end products of leucine metabolism are acetyl-CoA and acetoacetate; consequently, it is one of the two exclusively ketogenic amino acids, with lysine being the other. Leucine is concentrated in muscle tissues in humans, and like other BCAAs (isoleucine and valine) it is mostly oxidized in skeletal muscles rather than the liver.
2. Natural Sources
L-leucine is essential in humans and animals, meaning the body cannot synthesize it; it must be obtained from the diet. Human dietary sources are foods that contain protein, such as meats, dairy products, soy products, and beans and other legumes. Major dietary sources of leucine include high-protein animal products, dairy products, eggs, pulses, and whole grains. Good dietary sources include salmon, tuna, brown rice, corn, eggs, beans (including chickpeas and soybeans), and nuts including pine nuts, almonds, Brazil nuts, and pistachios.
Leucine is the most abundant branched-chain amino acid (BCAA) found in animal and plant proteins. Common protein sources of leucine are dairy proteins such as whey, casein, micellar casein, caseinate, and glycomacropeptide (GMP), and vegetable proteins such as wheat, rice, pea, lupine, and soy proteins.
Among the first of the amino acids to be discovered (1819), leucine is present in large proportions (about 15 percent) in hemoglobin, the oxygen-carrying pigment of red blood cells. In plants and microorganisms, biosynthesis follows a different route: in plants and microorganisms, leucine is synthesized from pyruvic acid, a product of the breakdown of carbohydrates.
3. Common Forms and Preparations as a Supplement
L-leucine is the naturally occurring enantiomer incorporated into proteins during ribosomal protein synthesis and is the most widely used form in amino acid research, cell culture studies, formulation development, peptide synthesis, and metabolic investigations. As a dietary supplement, L-leucine is commercially available in several forms:
- Free amino acid powder: Crystalline L-leucine powder is the most common supplemental form, sold as a standalone product or blended into BCAA mixtures.
- BCAA blends: Leucine is a branched-chain amino acid (BCAA) and is found in BCAA supplements along with isoleucine and valine.
- Protein-bound form: Leucine may be used as a free amino acid, or in a bound form, such as a dipeptide, an oligopeptide, a polypeptide, or as part of a protein.
- Commercial production: L-leucine is commonly associated with fermentation-based production. Amino acid fermentation is an important production route for L-leucine because it can provide the natural L-configuration at practical scale.
4. Historical and Scientific Discovery
Unlike many herbal ingredients or plant-derived supplements, L-leucine has no documented traditional medicinal use predating its chemical identification. Its history is rooted entirely in the scientific discovery of amino acids during the nineteenth century.
One of the first amino acids to be discovered, leucine was first obtained from cheese in 1819 by the French chemist Proust. In 1820, Braconnot used acid hydrolysis to isolate leucine from skeletal muscle and wool, and gave the substance its name. Its structure was not identified until 1891, when Schulze synthesized leucine from isovaleraldehyde. Leucine was first identified as essential for optimal growth in humans in 1935.
The use of L-leucine as a deliberate dietary supplement or pharmaceutical-grade ingredient emerged primarily in the latter decades of the twentieth century, coinciding with growing understanding of its role in protein metabolism, and accelerated significantly following the identification of the mTOR (mechanistic target of rapamycin) signaling pathway as a central mediator of anabolic responses in skeletal muscle.
5. Key Constituents, Metabolites, and Active Compounds
L-leucine itself is the primary active compound, but several metabolites generated from its catabolism have independent biological significance.
5.1 L-Leucine (Parent Molecule)
Leucine and β-hydroxy-β-methylbutyric acid (HMB), a minor leucine metabolite, exhibit pharmacological activity in humans and have been demonstrated to promote protein biosynthesis via the phosphorylation of the mechanistic target of rapamycin.
5.2 β-Hydroxy-β-Methylbutyrate (HMB)
HMB is a metabolite of the amino acid leucine that is naturally produced in both humans and other animals. Leucine not incorporated into muscle protein is ultimately oxidized through intermediates such as HMB, which itself is reported to enhance muscle mass and function in rats and humans. The metabolic pathway proceeds through α-ketoisocaproic acid (KIC): ¹⁴C-HMB appears in plasma and urine following an oral dose of ¹⁴C-leucine. ¹⁴C-leucine appears in plasma as ¹⁴C-α-ketoisocaproic acid (KIC) with a slower time course than ¹⁴C-HMB, a putative product of KIC.
5.3 α-Ketoisocaproic Acid (KIC)
Leucine may stimulate protein synthesis directly or through its metabolite, α-ketoisocaproic acid. KIC itself has been studied for anabolic properties but is less commercially prominent than either leucine or HMB.
6. Mechanisms of Action
6.1 mTORC1-Mediated Stimulation of Protein Synthesis
The best-established mechanism by which L-leucine exerts its anabolic effects is through activation of the mTOR complex 1 (mTORC1) signaling pathway. Leucine and essential amino acids appear to stimulate human muscle protein synthesis primarily by activating the mTOR signalling pathway.
The anabolic actions of leucine and insulin appear to activate independent intracellular signalling pathways which converge at the mammalian target of rapamycin (mTOR) and eventually affect translation initiation and elongation. Specifically, insulin activates phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB/Akt). Akt phosphorylates and inhibits tuberous sclerosis complex (TSC2), which relieves inhibition on Rheb (Ras homologue enriched in brain) and allows activation of mTOR.
The downstream effects of mTORC1 activation have been elucidated in mechanistic studies. Rapamycin completely blocked leucine-induced muscle protein synthesis and markedly reduced raptor-mTOR association, an indicator of mTORC1 activation. Rapamycin also blocked the leucine-induced phosphorylation of mTOR, S6 kinase 1 (S6K1), and eukaryotic initiation factor (eIF)4E-binding protein-1 (4E-BP1), and formation of the eIF4E·eIF4G complex.
L-leucine is an essential non-polar aliphatic, branched-chain amino acid which activates the transducer of regulated cAMP response element-binding protein activity 1 (TORC1) in human skeletal muscle. The activation of TORC1 contributes to the initial stimulus of muscle protein synthesis, increasing the availability of amino acids through translation.
6.2 Inhibition of Muscle Protein Breakdown
Dietary leucine has been shown to suppress the rate of myofibrillar protein degradation and muscle weight loss in rats. Leucine also stimulates muscle protein synthesis and modulates the activity of various proteins involved in the control of mRNA translation.
6.3 Insulin Secretion and Glucose Homeostasis
Kalogeropoulou et al. (2008) reported that the tandem ingestion of leucine and glucose synergistically stimulated insulin secretion and lowered blood glucose in humans. In addition to its effects on protein synthesis and degradation, leucine also stimulates glucose uptake by protein kinase C (PKC), while insulin modulates glucose uptake via protein kinase B.
6.4 Energy and Lipid Metabolism
Leucine has a strong effect on energy and lipid metabolism. Increased energy expenditure and toxic lipids removal by increasing the prevalence and activity of leucine may be a promising therapeutic strategy to treat obesity and its consequent conditions.
Leucine activates the signaling factor mTOR to promote protein synthesis in skeletal muscle and in adipose tissue. It is also a major regulator of the mTOR-sensitive response of food intake to a high-protein diet.
6.5 Energy Substrate in Exercise
Leucine, once catalyzed, contributes to ATP production, which is vital when moving from rest to exercise.
6.6 HMB Mechanism of Action (Downstream)
The primary mode of action of HMB appears to be through its dual mechanism to enhance muscle protein synthesis and suppress muscle protein breakdown. HMB's activation of mTORC1 is independent of the leucine-sensing pathway (Sestrin2-GATOR2 complex).
7. Scientific Evidence by Area of Use
7.1 Skeletal Muscle Protein Synthesis and Athletic Performance
Overview of evidence: This is the area of application with the largest and most consistent body of evidence, encompassing both mechanistic (animal and cell-based) and human clinical data.
Human and clinical studies: A published crossover study found that ingesting 23 g of protein with 5 g of added leucine achieved near-maximal fractional synthetic rate (FSR) after endurance exercise. Protein-leucine ingestion after strenuous endurance exercise was found to accentuate muscle protein synthesis and improve recovery of muscle performance. In this study, 12 trained men completed 100 minutes of high-intensity cycling and then ingested protein/leucine/carbohydrate/fat combinations in varying doses during recovery.
When compared to sedentary conditions, leucine supplementation more potently activated mTORC1 and protein synthesis in acutely exercised muscle.
New and emerging studies have focused on supplementing leucine-enriched whey protein and resistance training in older adults to mitigate the effects of sarcopenia, including significant muscle mass loss. The biochemical mechanisms underlying the anabolic properties of leucine, including its role in protein synthesis and mTOR signalling pathways, were explored, and findings from reviewed studies indicate that the combined intervention of leucine-enriched whey protein supplementation and resistance training elicits favourable outcomes.
Evidence strength: Human mechanistic data are robust for leucine's acute stimulation of muscle protein synthesis via mTORC1. The translation of this acute signaling effect into meaningful long-term gains in muscle mass and strength in already-healthy populations is less consistently demonstrated in controlled trials, particularly when leucine is administered without an accompanying exercise stimulus or adequate background protein intake.
7.2 Sarcopenia and Muscle Preservation in Older Adults
Clinical trial evidence: One randomized, placebo-controlled, double-blind trial in fifty participants aged 65 and over assessed the efficacy of leucine administration on muscle mass, muscle strength, functional performance, and respiratory muscle function. Participants received a daily intake of leucine (6 g/day) or placebo (lactose, 6 g/day) for 13 weeks. Administration of leucine was well-tolerated and significantly improved some criteria of sarcopenia, including functional performance measured by walking time (p = 0.011), and improved lean mass index. The leucine-treated group also improved significantly (p = 0.026) in maximum static expiratory force compared to placebo. No significant effects on functional impairment, cognitive function, nutritional assessment, or inflammatory cytokines (IL-6, TNF-alpha) were observed.
However, a separate large RCT showed no benefit: In the LACE randomized controlled trial, for leucine (n = 72, mean age 78) versus no leucine (n = 72, mean age 79), leucine did not improve the primary outcome (adjusted treatment effect 0.1 point, 95% CI −1.0 to 1.1; P = 0.90). No significant treatment benefit was seen for any secondary outcome, including muscle mass (adjusted treatment effect −0.3 kg, 95% CI −1.0 to 0.4; P = 0.47).
Systematic review and meta-analysis findings: A 2022 systematic review and meta-analysis encompassing 17 randomized controlled trials reached a nuanced conclusion: leucine-isolated supplementation did not improve muscle mass and strength in elderly individuals. However, leucine-combined supplementation including vitamin D exhibited a significant benefit for muscle strength and performance, including handgrip strength and gait speed, in older adults. A combination of nutritional supplements would be a viable option for improving sarcopenia.
Studies suggested that L-leucine supplementation was able to enhance muscle protein synthesis in the elderly. Some RCTs indicated that leucine could improve clinical indicators of sarcopenia, including functional performance and bone mineral-free lean tissue mass. In contrast, several trials reported that prolonged leucine supplementation could not modulate body composition, muscle mass, and strength in elderly individuals.
Evidence strength: Moderate. Evidence for acute increases in muscle protein synthesis in the elderly is reasonably consistent, but whether this translates to measurable gains in muscle mass or physical performance over weeks or months remains mixed and context-dependent. Combined approaches (leucine plus vitamin D, resistance exercise, or adequate total protein) appear more promising than leucine supplementation in isolation.
7.3 Glucose Metabolism and Metabolic Syndrome
Clinical and epidemiological evidence: The relationship between L-leucine and glucose/insulin metabolism is complex and not fully resolved. Evidence points in conflicting directions depending on the study context.
A cross-sectional epidemiological study found: a significant inverse association between dietary BCAA (including leucine) intake and metabolic syndrome, hyperglycemia, and hypertriglyceridemia, regardless of confounding factors.
Preclinical data in rodent models have been informative: doubling dietary leucine reversed many metabolite abnormalities and caused a marked improvement in glucose tolerance and insulin signaling without altering food intake or weight gain. Increased dietary leucine was also associated with a decrease in hepatic steatosis and a decrease in inflammation in adipose tissue.
A human RCT in adults at metabolic syndrome risk used 3 g/day of leucine supplementation for 8 weeks alongside energy restriction. The study determined whether leucine supplementation during energy restriction blunted the loss of fat-free mass (FFM) and improved glucose tolerance. Thirty-seven adults aged 20–65 years with increased waist circumference and at least one other metabolic syndrome component were enrolled in a two-arm parallel, double-blind, randomized controlled trial, receiving 3 g/day leucine or placebo for 8 weeks.
However, conflicting data suggest a more cautious interpretation: elevated plasma levels of the BCAA leucine are associated with obesity and insulin resistance (IR) and thus the propensity for type 2 diabetes mellitus development. However, other clinical studies suggest the contradictory view that leucine may in fact offer a degree of protection against metabolic syndrome.
Data indicate that leucine treatment acutely induces insulin secretion. Under high-fat dietary conditions in animal models, leucine mediates beneficial effects on adiposity and insulin sensitivity, in part due to increasing energy expenditure.
Evidence strength: Mixed and preliminary. The association between circulating BCAA levels and insulin resistance is a consistent epidemiological observation, but the directionality of the causal relationship has not been clearly established in humans. Whether supplemental L-leucine improves or worsens glucose regulation likely depends on dose, dietary context, and baseline metabolic health. No strong consensus from clinical trials currently exists.
7.4 Body Composition During Energy Restriction
Leucine has a strong effect on energy and lipid metabolism. Increased energy expenditure and toxic lipids removal by increasing the prevalence and activity of leucine may be a promising therapeutic strategy to treat obesity and its consequent conditions. Animal studies have shown that dietary restriction of leucine and the other BCAAs can reverse diet-induced obesity in wild-type mice by increasing energy expenditure, and can restrict fat mass gain of hyperphagic rats. However, paradoxically, leucine restriction — rather than supplementation — was the beneficial intervention in these animal models. Human evidence for leucine supplementation specifically improving body composition outcomes during caloric restriction requires further investigation.
Evidence strength: Largely preclinical (animal and cell-based). Human clinical data are limited and not yet conclusive.
7.5 Liver Disease and Hyperammonemia
There is emerging research interest in L-leucine supplementation in the context of liver cirrhosis and hyperammonemia-related muscle wasting. Increased skeletal muscle ammonia uptake with loss of muscle mass adversely affects clinical outcomes in cirrhosis. Hyperammonemia causes reduced protein synthesis and sarcopenia. Research has investigated the cellular responses and the molecular mechanism of L-leucine-induced adaptation to ammonia-induced stress, including impaired mTORC1 signaling observed in skeletal muscle from cirrhotic patients.
Evidence strength: Preliminary and largely mechanistic. Clinical application of leucine supplementation in liver disease requires further human trial data before clinical recommendations can be made.
8. Body Systems Associated with L-Leucine
- Musculoskeletal system: Leucine helps regulate blood-sugar levels, stimulates muscle protein synthesis, and promotes growth of muscle and bone tissues.
- Endocrine/pancreatic system: L-leucine directly stimulates insulin secretion from pancreatic beta cells, particularly in the co-presence of glucose.
- Metabolic system: As a ketogenic amino acid, leucine contributes acetyl-CoA and acetoacetate to energy metabolism, and plays a central role in regulating the cellular nutrient-sensing machinery.
- Hepatic system: Leucine influences hepatic glucose and lipid homeostasis. Research observations provide insight into the clinical consequences of excess plasma leucine, particularly for hyperglycemia, insulin resistance, and nonalcoholic fatty liver disease (NAFLD).
- Central nervous system: BCAAs including leucine share transport mechanisms with other large neutral amino acids across the blood-brain barrier, and extreme accumulation (as in maple syrup urine disease) results in severe neurological effects. Leucine toxicity, as seen in decompensated maple syrup urine disease, causes delirium and neurologic compromise, and can be life-threatening.
- Respiratory system: In a clinical trial in sarcopenic elderly participants, the leucine-treated group improved significantly (p = 0.026) in maximum static expiratory force compared to placebo.
9. Dosage Forms and Dosages Reported in Studies
The following dosages are reported as used in specific published studies and are not general recommendations.
- Sarcopenia / older adults — 6 g/day: A double-blind, placebo-controlled, randomized trial in 50 participants aged 65 and over used a parallel group intervention of 13 weeks' duration with a daily intake of leucine (6 g/day) or placebo.
- Post-endurance exercise — 5 g added to 23 g protein: Ingesting 23 g of protein with 5 g of added leucine achieved near-maximal fractional synthetic rate after endurance exercise.
- Resistance exercise — 3 g post-exercise: In a study of trained young men (ages 18–30), participants orally ingested 3 grams of L-leucine (0.043 g/kg equivalent) immediately after each resistance exercise session.
- Metabolic syndrome — 3 g/day: An 8-week RCT in adults at risk of metabolic syndrome assigned the intervention group to leucine at 3 g/day while following an energy-restricted diet.
- Toxicological dose-escalation study: In a safety study, five healthy men each received graded stepwise increases in leucine intakes of 50, 150, 250, 500, 750, 1000, and 1250 mg·kg⁻¹·d⁻¹ corresponding to the Estimated Average Requirement and multiples thereof.
- General supplemental / BCAA context: In one patent-documented embodiment, an anabolic amino acid was provided in a daily dosage of 1 to 10 g, with L-leucine as the preferred component.
Because the three BCAAs (leucine, valine, and isoleucine) are typically consumed together, they tend to be studied as a group, though there are important differences in their synthesis and functions.
10. Safety Considerations and Interactions
10.1 General Tolerability at Study Doses
Most of the research into leucine consumption has focused on efficacy. Very few studies have sought to determine the maximum safe level of intake. Limited evidence suggests that intakes of ≤1250 mg·kg⁻¹·d⁻¹ do not appear to have any health consequences other than short-term elevated plasma ammonia concentrations. One subject experienced gastrointestinal distress after consuming 1000 mg/kg and did not complete a dose-escalation safety study.
10.2 Suggested Upper Intake Level
Leucine at a dose exceeding 500 mg/kg/d was observed with hyperammonemia. As such, unofficially, a tolerable upper intake level (UL) for leucine in healthy adult men can be suggested at 500 mg/kg/d or 35 g/d under acute dietary conditions.
10.3 Hyperammonemia
Leucine at a dose exceeding 500 mg/kg/d was observed with hyperammonemia. As such, a tolerable upper intake level for leucine in healthy adult men can be suggested at 500 mg/kg/d or 35 g/d under acute dietary conditions.
10.4 Pellagra and Niacin Deficiency
A high intake of leucine may cause or exacerbate symptoms of pellagra in people with low niacin status because it interferes with the conversion of L-tryptophan to niacin. Animal models suggest that very high doses of L-leucine (in rodent models at 15 g/kg) may lead to pellagra-like symptoms due to disruption of tryptophan metabolism.
10.5 Insulin Resistance Association
High blood levels of leucine are associated with insulin resistance in humans, mice, and rodents. This might be due to the effect of leucine to stimulate mTOR signaling. It is important to note that this association is observed for chronically elevated plasma leucine and is distinct from the acute, short-term use of supplemental leucine in the context of adequate overall dietary patterns.
10.6 Maple Syrup Urine Disease (MSUD) — Contraindicated Context
MSUD is caused by a defect in the branched-chain alpha-ketoacid dehydrogenase enzyme complex, resulting in the accumulation of branched-chain amino acids (BCAAs) and the corresponding branched-chain keto acids. This accumulation is thought to have specific neurological implications, and immediate treatment is required to avoid irreversible impairment. In individuals with MSUD, additional leucine intake is contraindicated; management requires strict leucine restriction.
10.7 Drug Interactions
L-leucine also has a synergistic effect on the action of phosphodiesterase 5 (PDE5) inhibitors and may lead to interactions with medications such as sildenafil. This reported interaction has been noted in clinical trial safety documentation but has not been characterized in depth in the primary literature.
10.8 Hypoglycemia at Very High Doses
Excessive intake of L-leucine (greater than 750 mg/kg body weight) may result in hypoglycemia. L-leucine ingested up to a 200 mg/kg dose has no effect on plasma insulin or glucose.
10.9 Safety of the Leucine Metabolite HMB
No adverse events have been reported for the leucine metabolite β-hydroxy-β-methylbutyrate (HMB), although no studies have tested HMB toxicity in humans. Future research is needed to evaluate leucine and HMB toxicity in the elderly and in specific health conditions.
11. Limitations of Current Evidence
The following limitations apply across the L-leucine literature:
- Many studies investigate leucine as part of BCAA blends or as an addition to protein supplements, making it difficult to isolate the contribution of L-leucine alone.
- Most mechanistic evidence for mTOR activation derives from animal (particularly neonatal pig) and cell culture models, with direct human mechanistic data less extensive.
- The value of chronic leucine ingestion for muscle growth is still unclear.
- The relationship between leucine, circulating BCAA levels, and insulin resistance/diabetes risk is epidemiological in nature and causality has not been established in humans.
- Several trials reported that prolonged leucine supplementation could not modulate body composition, muscle mass, and strength in elderly individuals. These inconsistent findings motivated comprehensive systematic reviews.
References
Go back